DK1662007T3 - Forebyggende middel eller lægemiddel til inflammatoriske tarmsygdomme indeholdende anti-CD81-antistof som den aktive bestanddel - Google Patents

Forebyggende middel eller lægemiddel til inflammatoriske tarmsygdomme indeholdende anti-CD81-antistof som den aktive bestanddel

Info

Publication number
DK1662007T3
DK1662007T3 DK04772572.6T DK04772572T DK1662007T3 DK 1662007 T3 DK1662007 T3 DK 1662007T3 DK 04772572 T DK04772572 T DK 04772572T DK 1662007 T3 DK1662007 T3 DK 1662007T3
Authority
DK
Denmark
Prior art keywords
drug
antibody
active ingredient
inflammatory bowel
bowel disease
Prior art date
Application number
DK04772572.6T
Other languages
English (en)
Inventor
Takamasa Watanabe
Kaoru Kikuchi
Original Assignee
Dainippon Sumitomo Pharma Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dainippon Sumitomo Pharma Co filed Critical Dainippon Sumitomo Pharma Co
Application granted granted Critical
Publication of DK1662007T3 publication Critical patent/DK1662007T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/06—Gastro-intestinal diseases
    • G01N2800/065—Bowel diseases, e.g. Crohn, ulcerative colitis, IBS

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Veterinary Medicine (AREA)
  • Pathology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
DK04772572.6T 2003-08-28 2004-08-25 Forebyggende middel eller lægemiddel til inflammatoriske tarmsygdomme indeholdende anti-CD81-antistof som den aktive bestanddel DK1662007T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2003304264 2003-08-28
PCT/JP2004/012616 WO2005021792A1 (ja) 2003-08-28 2004-08-25 抗ｃｄ８１抗体を有効成分として含有する炎症性腸疾患の予防または治療剤

Publications (1)

Publication Number Publication Date
DK1662007T3 true DK1662007T3 (da) 2011-06-14

Family

ID=34269264

Family Applications (1)

Application Number Title Priority Date Filing Date
DK04772572.6T DK1662007T3 (da) 2003-08-28 2004-08-25 Forebyggende middel eller lægemiddel til inflammatoriske tarmsygdomme indeholdende anti-CD81-antistof som den aktive bestanddel

Country Status (7)

Country Link
US (1) US20060275289A1 (da)
EP (1) EP1662007B9 (da)
JP (1) JP4749861B2 (da)
AT (1) ATE509635T1 (da)
DK (1) DK1662007T3 (da)
ES (1) ES2363770T3 (da)
WO (1) WO2005021792A1 (da)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100168210A1 (en) * 2007-06-05 2010-07-01 Edwards Iii Carl Keith T-Cell Cytokine-Inducing Surface Molecules and Methods of Use
WO2011108638A1 (ja) 2010-03-04 2011-09-09 大日本住友製薬株式会社 炎症性腸疾患用薬剤
US8440797B2 (en) 2010-12-06 2013-05-14 Dainippon Sumitomo Pharma Co., Ltd. Human monoclonal antibody
JP6029470B2 (ja) * 2010-12-06 2016-11-24 大日本住友製薬株式会社 ヒトモノクローナル抗体

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6423501B2 (en) * 1996-12-13 2002-07-23 Beth Israel Deaconess Medical Center Calcium-independent negative regulation by CD81 of receptor signaling
PT1021534E (pt) * 1997-10-06 2010-03-03 Novartis Vaccines & Diagnostic Proteina cd81 receptora da hepatite c
US20030113914A1 (en) * 2001-12-10 2003-06-19 Isis Pharmaceuticals, Inc. Antisense modulation of CD81 expression
US7820161B1 (en) * 1999-05-07 2010-10-26 Biogen Idec, Inc. Treatment of autoimmune diseases
EP1256348B1 (en) * 2000-02-14 2012-05-02 Mitsubishi Tanabe Pharma Corporation Remedies for hepatitis c
JP2001299140A (ja) * 2000-04-24 2001-10-30 Sumitomo Pharmaceut Co Ltd Ｈｃｖを増幅しうる細胞及び非ヒト動物
WO2002006329A2 (en) * 2000-07-18 2002-01-24 Curagen Corporation Human polynucleotides and polypeptides encoded thereby
MXPA03002262A (es) * 2000-09-18 2003-10-15 Idec Pharma Corp Terapia de combinacion para tratamiento de enfermedades autoinmunes usando una combinacion de anticuerpos inmunorreguladores/supresores de celulas b.
JP3816763B2 (ja) * 2001-06-18 2006-08-30 住友金属パイプエンジ株式会社 管内検査装置及び管内検査方法
JP2003230388A (ja) * 2001-12-05 2003-08-19 Sumitomo Pharmaceut Co Ltd 糖・脂質代謝異常疾患マーカーおよびその利用
JP2003235573A (ja) * 2002-02-13 2003-08-26 Sumitomo Pharmaceut Co Ltd 糖尿病性腎症マーカーおよびその利用

Also Published As

Publication number Publication date
JPWO2005021792A1 (ja) 2006-10-26
EP1662007B9 (en) 2012-02-29
WO2005021792A1 (ja) 2005-03-10
EP1662007A4 (en) 2007-10-31
EP1662007A1 (en) 2006-05-31
JP4749861B2 (ja) 2011-08-17
US20060275289A1 (en) 2006-12-07
EP1662007B1 (en) 2011-05-18
ATE509635T1 (de) 2011-06-15
ES2363770T3 (es) 2011-08-16

Similar Documents

Publication Publication Date Title
KR950031059A (ko) 골다공증 치료용 약제학적 조성물
ES2282685T3 (es) Derivados de hidroxietilamina para el tratamiento de la enfermedad de alzheimer.
ATE443043T1 (de) Phenylcarboxamide als beta-sekretase-hemmer zur behandlung von alzheimer
HRP20030139B8 (hr) Peptidomimetiäśki inhibitori proteaza
BR0313371A (pt) Composto, uso de um composto e método de tratamento de doença
NO2013019I1 (no) Kombinasjon omfattende aliskiren, som den frie basen eller som et farmasøytisk akseptabelt salt derav, og hydroklortiazid eller et farmasøytisk akseptabelt salt derav.
ECSP055701A (es) Nuevos derivados de pirimidinamida y el uso de los mismos
BG66085B1 (bg) Фенилаланинови производни
SE0001899D0 (sv) New compounds
BR9908332A (pt) Derivados de n-[carbonil(anel di ou triaza diinsaturado de cinco membros substituìdo)] derivados de guanidina para tratamento de esquemia
ATE466014T1 (de) Spiroazacyclische verbindungen als monoaminrezeptormodulatoren
DK254787A (da) Farmaceutiske praeparater til behandling af sygdomme foraarsaget af oxidativt stress og indeholdende 2-phenyl.1,2-benziso-selenazol-3(2h)-on som aktiv bestanddel
FR2786664B1 (fr) Procede de traitement de fruits et legumes utilisant l'eugenol et/ou l'isoeugenol et utilisation d'une composition a base d'eugenol et/ou d'isoeugenol
EA200501690A1 (ru) Композиция, включающая ингибитор pde4 и ингибитор pde5
BR9813651A (pt) Compostos antipicornavirais e métodos para o seu uso e preparação
EA200200207A1 (ru) Применение антагонистов cgrp и ингибиторов высвобождения cgrp для устранения приливов в период менопаузы
BR0309278A (pt) Composto, composição, métodos para modular a atividade da cinesina ksp, para inibir a ksp, para o tratamento de uma doença proliferativa celular, e, uso de um composto
KR950031060A (ko) 골다공증 치료용 약제학적 조성물
ATE290548T1 (de) Expressionsblockierung von virulenten faktoren in s. aureus
SE9804212D0 (sv) Compounds
DK1662007T3 (da) Forebyggende middel eller lægemiddel til inflammatoriske tarmsygdomme indeholdende anti-CD81-antistof som den aktive bestanddel
DE60134735D1 (de) Neue neurokinin-antagonisten zum gebrauch als arzneimittel
TNSN03065A1 (en) BIOPESTICIDE COMPOSITIONS
ATE187956T1 (de) Substituierte kondensierte und verbrückte bicyclische verbindungen als therapeutische mittel
BR9812131A (pt) Composições contendo bergamotina para aumentar a biodisponibilidade oral de agentes farmacêuticos